AstraZeneca has licensed six monoclonal antibodies from Vanderbilt University and plans to advance the most promising ones for prevention and treatment of COVID-19.

Monoclonal antibodies are synthesized versions of natural antibodies that may be able to neutralize the SARS-CoV-2 virus.

The company said it plans to begin a study of two antibodies as a combination treatment within the next two months.